Drugs for Thyroid Cancer, Nonmedullary, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 132)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Aztreonam |
Approved |
Phase 4 |
|
78110-38-0 |
5742832 |
Synonyms:
(Z,)-2-((((2-Amino-4-thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulfO-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionate
(Z,)-2-((((2-Amino-4-thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulfO-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionic acid
(Z,)-2-((((2-Amino-4-thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulphO-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionate
(Z,)-2-((((2-Amino-4-thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulphO-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionic acid
2-({[(1Z)-1-(2-AMINO-1,3-THIAZOL-4-YL) -2- {[(2S,3S)-2-METHYL-4-OXO-1-SULFOAZETIDIN-3-YL]AMINO} -2- OXOETHYLIDENE]AMINO}OXY)-2-METHYLPROPANOIC ACID
Az threonam
Azactam
AZT
Azthreonam
Az-threonam
AZTREONAM
AZTRÉONAM
Aztreonam esteve brand
Aztreonam squibb brand
|
Aztreonamum
Bristol myers squibb brand OF aztreonam
Bristol-myers squibb brand OF aztreonam
CAYSTON
Esteve brand OF aztreonam
Monobactam
NSC-646279
Primbactam
Sanofi winthrop brand OF aztreonam
SO-26776
SQ 26776
SQ-26776
Squibb brand OF aztreonam
Urobactam
|
|
2 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
3 |
|
Anti-Bacterial Agents |
|
Phase 4 |
|
|
|
4 |
|
Antibiotics, Antitubercular |
|
Phase 4 |
|
|
|
5 |
|
Prazosin |
Approved |
Phase 3 |
|
19216-56-9 |
4893 |
Synonyms:
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine
2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline
CP-12299
CP-122991
CP-12299-1
CP-12299-1|Hypovase®|Minipress®|prazosine
Douglas brand OF prazosin hydrochloride
Furazosin
HCL, Prazosin
Hydrochloride, prazosin
HYPOVASE
|
Minipress
Pfizer brand OF prazosin hydrochloride
Pratsiol
Prazocin
Prazosin
Prazosin HCL
Prazosin hydrochloride
Prazosina
Prazosine
Prazosinum
|
|
6 |
|
Zoledronic acid |
Approved |
Phase 3 |
|
118072-93-8 |
68740 |
Synonyms:
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonate
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonate
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
2-(Imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
ácido zoledrónico
ACLASTA
Aclasta®|CGP-42446|CGP-42446A|Reclast®|zoledronate|Zometa®
ANHYDROUS ZOLEDRONIC ACID
CGP-42446
CGP-42446A
Novartis brand OF zoledronic acid
|
Reclast
ZERLINDA
ZOL
ZOL446
ZOLEDRONATE
Zoledronic acid
Zoledronic acid anhydrous
ZOLEDRONIC ACID HYDRATE
ZOLEDRONIC ACID MONOHYDRATE
ZOLEDRONIC ACID, ANHYDROUS
Zometa
Zometa Concentrate
|
|
7 |
|
Docetaxel |
Approved, Investigational |
Phase 3 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
8 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
9 |
|
Adrenergic Antagonists |
|
Phase 3 |
|
|
|
10 |
|
Adrenergic alpha-Antagonists |
|
Phase 3 |
|
|
|
11 |
|
Adrenergic alpha-1 Receptor Antagonists |
|
Phase 3 |
|
|
|
12 |
|
Adrenergic Agents |
|
Phase 3 |
|
|
|
13 |
|
Antihypertensive Agents |
|
Phase 3 |
|
|
|
14 |
|
Iodine |
Approved, Investigational |
Phase 2 |
|
7553-56-2 |
807 |
Synonyms:
Cadex
Diiodine
I2
Iode
Iodine
Iodine 127
Iodine-127
Iodine-molecule
|
Iodio
iodo
Iodum
Jod
Jood
Molecular iodine
NSC-42355
Tincture iodine
|
|
15 |
|
Calcium carbonate |
Approved, Investigational |
Phase 2 |
|
471-34-1 |
|
Synonyms:
Aragonite
CaCO3
Calcio carbonato
Calcite
Calcium carbonate
Calcium carbonate (1:1)
Calcium carbonate, precipitated
Calcium carbonic acid
Calcium carbonic acid (1:1)
Calcium carbonic acid, precipitated
Calcium milk
Calciumcarbonat
Cal-sup
Carbonate calcium salt (1:1)
Carbonate de calcium
|
Carbonate, calcium
Carbonato de calcio
Carbonic acid calcium salt (1:1)
Carbonic acid de calcium
Chalk
e 170
Kalziumkarbonat
Kohlensaurer kalk
Limestone
Marble
Milk OF calcium
Precipitated calcium carbonate
Precipitated calcium carbonic acid
Vaterite
|
|
16 |
|
Bortezomib |
Approved, Investigational |
Phase 2 |
|
179324-69-7 |
387447 93860 |
Synonyms:
[(1R)-3-METHYL-1-({(2S)-3-PHENYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO]PROPANOYL}AMINO)BUTYL]BORONIC ACID
341, PS
BORTEZOMIB
BORTEZOMIB HYDRATE
LDP 341
LDP-341
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
|
NSC-681239
PEPTIDE BORONATE
peptide boronate|PS-341|Velcade®
PS 341
PS-341
Velcade
|
|
17 |
|
Sunitinib |
Approved, Investigational |
Phase 2 |
|
557795-19-4 |
5329102 |
Synonyms:
5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
SU011248
SU-011248
SU11248
SU-11248
|
SU11248|Sutent®
SUNITINIB
Sunitinib malate
Sunitinibum
Sutent
|
|
18 |
|
Decitabine |
Approved, Investigational |
Phase 2 |
|
2353-33-5 |
451668 |
Synonyms:
2' Deoxy 5 azacytidine
2'-Deoxy-5-azacytidine
4-Amino-1-(2-deoxy-b-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one
4-Amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one
5 Aza 2' deoxycytidine
5 Azadeoxycytidine
5 Deoxyazacytidine
5-Aza-2'-deoxycytidine
5AzadC
5-AzadC
5-Azadeoxycytidine
|
5-Deoxyazacytidine
Azadc
AzadC compound
Compound, azadc
DAC
Dacogen
Decitabina
Decitabine
Decitabine mesylate
Dezocitidine
Mesylate, decitabine
NSC-127716
|
|
19 |
|
Azacitidine |
Approved, Investigational |
Phase 2 |
|
320-67-2 |
9444 |
Synonyms:
4-Amino-1-b-D-ribofuranosyl-S-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-S-triazin-2(1H)-one
4-Amino-1-β-D-ribofuranosyl-S-triazin-2(1H)-one
5 Azacytidine
5 AZC
5-AZAC
5-azacytidine
Azacitidina
|
Azacitidine
Azacitidinum
Azacytidine
LADAKAMYCIN
NSC-102816
Pharmion brand OF azacitidine
U-18496
Vidaza
|
|
20 |
|
Vorinostat |
Approved, Investigational |
Phase 2 |
|
149647-78-9 |
5311 |
Synonyms:
18F Suberoylanilide hydroxamic acid
18F-SAHA
18F-Suberoylanilide hydroxamic acid
Merck brand OF vorinostat
MK0683
MK-0683
MK-0683|MK0683|SAHA|suberoylanilide hydroxamic acid|Zolinza®
N Hydroxy n' phenyloctanediamide
N1 Hydroxy N8 phenyloctanediamide
N1-Hydroxy-N8-phenyloctanediamide
NHNPODA
N-Hydroxy-n'-phenyloctanediamide
N-Hyrdroxy-n'-phenyloctanediamide
|
Octanedioate hydroxyamide phenylamide
Octanedioic acid hydroxyamide phenylamide
SAHA
SHH
Suberanilohydroxamate
Suberanilohydroxamic acid
Suberoyl anilide hydroxamic acid
Suberoylanilide hydroxamate
Suberoylanilide hydroxamic acid
VORINOSTAT
Vorinostatum
Zolinza
|
|
21 |
|
Vemurafenib |
Approved |
Phase 2 |
|
918504-65-1 |
42611257 |
Synonyms:
BRAF(V600E) KINASE INHIBITOR RO5185426
N-[3-[[5-(4-CHLOROPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]CARBONYL]-2,4-DIFLUOROPHENYL]-1-PROPANESULFONAMIDE
PLX 4032
PLX4032
PLX-4032
PLX4032|RG7204|Zelboraf®
RG7204
|
RG-7204
RO-5185426
RO-51-85426
VEMURAFENIB
Vémurafénib
Vemurafenibum
Zelboraf
|
|
22 |
|
Romidepsin |
Approved, Investigational |
Phase 2 |
|
128517-07-7 |
5352062 |
Synonyms:
ANTIBIOTIC FR 901228
CHROMADAX
DEPSIPEPTIDE
FK228
FK-228
FK228|FR901228|Istodax®
FR901228
|
FR-901228
ISTODAX
NSC-630176
ROMIDEPSIN
Romidepsina
Romidepsine
Romidepsinum
|
|
23 |
|
Nivolumab |
Approved |
Phase 1, Phase 2 |
|
946414-94-4 |
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
24 |
|
Fluorouracil |
Approved |
Phase 1, Phase 2 |
|
51-21-8 |
3385 |
Synonyms:
5 Fluorouracil
5 Fluorouracil biosyn
5 FU
5 FU lederle
5 FU medac
5 HU hexal
5.F.U.
5-Fluoracil
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluracil
5FU
5-FU
5-FU lederle
5-FU medac
5-HU hexal
ACCUSITE
ACTIKERALL
Adrucil
Allergan brand OF fluorouracil
Arumel
Biosyn brand OF fluorouracil
Carac
Carzonal
CSP Brand OF fluorouracil
Dakota brand OF fluorouracil
Dakota, fluorouracile
Dermatech brand OF fluorouracil
Dermik brand OF fluorouracil
Effluderm
Efudex
Efudix
Efurix
Ferrer brand OF fluorouracil
Fluoro Uracil
Fluoro uracile icn
Fluoroblastin
Fluoroplex
Fluorouracil
Fluorouracil gry
Fluorouracil mononitrate
Fluorouracil monopotassium salt
Fluorouracil monosodium salt
Fluorouracil potassium salt
FLUORO-URACIL ROCHE
Fluorouracil teva brand
|
Fluorouracile dakota
Fluoro-uracile icn
Fluorouracil-gry
Fluorouracilo
Fluorouracilo ferrer far
Fluorouracilum
Fluoruracil
Fluouracil
Fluracedyl
FLURACIL
Fluracilum
Fluri
Fluril
Fluro Uracil
Flurodex
Flurouracil
Ftoruracil
FU
Gry brand OF fluorouracil
Haemato brand OF fluorouracil
Haemato fu
Haemato-fu
Hexal brand OF fluorouracil
ICN brand OF fluorouracil
Kecimeton
Medac brand OF fluorouracil
Neocorp brand OF fluorouracil
Neofluor
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
RO-29757
RO-2-9757
Roche brand OF fluorouracil
Teva brand OF fluorouracil
Timazin
TOLAK
Ulup
URF
|
|
25 |
|
Eflornithine |
Approved, Withdrawn |
Phase 1, Phase 2 |
|
70052-12-9 |
3009 |
Synonyms:
(RS)-2,5-diamino-2-(difluoromethyl)pentanoic acid
2-(difluoromethyl)ornithine
2-(difluoromethyl)ornithine (DMFO)|difluoromethylornithine|Ornidyl®|Vaniqa®
a-(Difluoromethyl)-DL-ornithine
a-Difluoromethylornithine
alpha Difluoromethyl ornithine
alpha Difluoromethylornithine
alpha-(Difluoromethyl)-DL-ornithine
alpha-Difluoromethyl ornithine
alpha-Difluoromethylornithine
DFMO
Difluoromethylornithine
DL alpha Difluoromethylornithine
DL-alpha-Difluoromethylornithine
|
Eflornithine
Eflornithine hydrochloride
Eflornithine monohydrochloride, monohydrate
Hydrochloride, eflornithine
MDL 71,782 a
MDL71,782 a
MDL-71,782 a
Monohydrochloride, monohydrate eflornithine
Ornidyl
Ornithine, alpha-difluoromethyl
Vaniqa
Women first brand OF eflornithine hydrochloride
Α-(difluoromethyl)-DL-ornithine
Α-difluoromethylornithine
|
|
26 |
|
Durvalumab |
Approved, Investigational |
Phase 2 |
|
1428935-60-7 |
|
Synonyms:
|
27 |
|
Tremelimumab |
Approved, Investigational |
Phase 2 |
|
745013-59-6 |
|
Synonyms:
CP-675,206
CP-675|CP-675,206|CP-675206|ticilimumab
CP-675206
|
TICILIMUMAB
TREMELIMUMAB
TREMELIMUMAB (GENETICAL RECOMBINATION)
|
|
28 |
|
Dabrafenib |
Approved, Investigational |
Phase 2 |
|
1195765-45-7 |
44462760 |
Synonyms:
DABRAFENIB
DRB436
GSK2118436
GSK-2118436
|
GSK2118436|GSK2118436A|Tafinlar®
GSK2118436a
GSK-2118436A
TAFINLAR
|
|
29 |
|
Carboplatin |
Approved |
Phase 2 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
30 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
31 |
|
Entrectinib |
Approved, Investigational |
Phase 2 |
|
1108743-60-7 |
25141092 |
Synonyms:
ENTRECTINIB
N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide
N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide
|
NMS-e628
RXDX-101
RXDX-101ENTRECTINIB
|
|
32 |
|
Crizotinib |
Approved, Investigational |
Phase 2 |
|
877399-52-5 |
11626560 |
Synonyms:
(<i>R</i>)-crizotinib|PF 2341066|PF-02341066|PF-2341066|PF2341066|Xalkori®
(R)-CRIZOTINIB
CRIZOTINIB
Crizotinibum
PF 2341066
|
PF-02341066
PF2341066
PF-2341066
XALKORI
|
|
33 |
|
Pralsetinib |
Approved, Investigational |
Phase 1, Phase 2 |
|
2097132-94-8 |
129073603 |
Synonyms:
(1R,4R)-N-[(1S)-1-[6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-{4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)imino]-1,6-dihydropyrimidin-2-yl}cyclohexane-1-carboximidate
BLU-667
BLU-667|BLU667|Gavreto®
|
N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide
PRALSETINIB
|
|
34 |
|
Trametinib |
Approved |
Phase 2 |
|
871700-17-3 |
11707110 |
Synonyms:
GSK 1120212
GSK1120212
GSK-1120212
GSK1120212|GSK1120212B|GSK212|JTP 74057|Mekinist®|trametinib dimethyl sulfoxide
GSK1120212B
GSK212
JTP 74057
|
JTP-74057
MEKINIST
TMT212
TRAMETINIB
TRAMÉTINIB
TRAMETINIB DIMETHYL SULFOXIDE
TRAMETINIBUM
|
|
35 |
|
Panitumumab |
Approved, Investigational |
Phase 2 |
|
339177-26-3 |
|
Synonyms:
ABX-EGF
ABX-EGF|ABX-EGF Mab|Vectibix®
E7.6.3
|
L01XC08
PANITUMUMAB
VECTIBIX
|
|
36 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
37 |
|
Doxorubicin |
Approved, Investigational |
Phase 2 |
|
23214-92-8 |
31703 |
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
ADM
ADR
Adriablastin
Adriablastine
Adriamycin
Adriamycin PFS
Adriamycin RDF
Adriamycin Semiquinone
Adriamycin®|Caelyx® (liposomal doxorubicin)|Doxil®|doxorubicin hydrochloride
Adriblastin
Adriblastina
Adriblastine
Adrimedac
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
Bristol-myers squibb brand OF doxorubicin hydrochloride
Caelyx
Cell pharm brand OF doxorubicin hydrochloride
Columbia brand OF doxorubicin hydrochloride
DM2
DOXIL
Doxo
Doxo cell
Doxo-cell
Doxolem
DOXORUBICIN
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
|
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
Elan brand OF doxorubicin hydrochloride
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
Hexal brand OF doxorubicin hydrochloride
Hydrochloride, doxorubicin
HYDROXYDAUNORUBICIN
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
Medac brand OF doxorubicin hydrochloride
Myocet
Neocorp brand OF doxorubicin hydrochloride
NSC-123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Tedec meiji brand OF doxorubicin hydrochloride
Urokit doxo cell
Urokit doxo-cell
VALRUBICIN IMPURITY, DOXORUBICIN
|
|
38 |
|
Sorafenib |
Approved, Investigational |
Phase 2 |
|
284461-73-0 |
216239 |
Synonyms:
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
BAY 43-9006
BAY 43-9006|BAY-439006|Nexavar®
BAY-43-9006
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
|
Nexavar
SORAFENIB
Sorafénib
Sorafenib N oxide
Sorafenib N-oxide
Sorafenib tosylate
Sorafenibum
|
|
39 |
|
Lenvatinib |
Approved, Investigational |
Phase 2 |
|
417716-92-8 |
9823820 |
Synonyms:
4-(3-chloro-4-((Cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide
4-(3-Chloro-4-(n'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide
4-{3-CHLORO-4-[(CYCLOPROPYLCARBAMOYL)AMINO]PHENOXY}-7-METHOXYQUINOLINE-6-CARBOXAMIDE
e 7080
E 7080|ER-203492-00|Kisplyx®|Lenvima®
e7080
E-7080
|
ER-203492-00
KISPLYX
LENVATINIB
LENVATINIB MESYLATE
Lenvima
UNII-ee083865g2
|
|
40 |
|
Salmon calcitonin |
Approved, Investigational |
Phase 2 |
|
47931-85-1 |
155817456 |
Synonyms:
CALCITONIN (SALMON SYNTHETIC)
Calcitonin salmon
CALCITONIN SALMON RECOMBINANT
Calcitonin, salmon
Calcitonina salmón sintética
|
Calcitonin-salmon
CT (salmon)|Miacalcin®
FORTICAL
Recombinant salmon calcitonin
Salmon calcitonin
|
|
41 |
|
Alfacalcidol |
Approved, Nutraceutical |
Phase 2 |
|
41294-56-8 |
5282181 |
Synonyms:
(5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-1a,3b-diol
(5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-1alpha,3beta-diol
(5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-1α,3β-diol
1 alpha-Hydroxycholecalciferol
1 alpha-Hydroxyvitamin D3
1a-Hydroxycholecalciferol
1a-Hydroxyvitamin D3
1a-Hydroxy-vitamin D3
1a-Hydroxyvitamin D3 / 1a-hydroxycholecalciferol
1alpha-Hydroxycholecalciferol
1alpha-Hydroxyvitamin D3
1alpha-Hydroxy-vitamin D3
1alpha-OHD3
1-alpha-Oxycholecalciferol
1-Hydroxycholecalciferol
1-Hydroxycholecalciferol, (1alpha,3alpha-(5Z,7E))-isomer
1-Hydroxycholecalciferol, (1beta)-(5Z)-isomer
1-Hydroxycholecalciferol, (1beta,3beta-(5E,7E))-isomer
1-Hydroxycholecalciferol, aluminum salt
1Α-hydroxycholecalciferol
|
1Α-hydroxyvitamin D3
1Α-hydroxy-vitamin D3
1Α-hydroxyvitamin D3 / 1α-hydroxycholecalciferol
9,10-Secocholesta-5,7,10(19)-triene-1a,3b-diol
9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta-diol
9,10-Secocholesta-5,7,10(19)-triene-1α,3β-diol
Alfacalcidol
Alfacalcidolum
AlfaD
Alphacalcidol
Alsiodol
Bondiol
Doss brand OF alfacalcidol
Eenalfadrie
EinsAlpha
Etalpha
Oksidevit
One-Alpha
Un-alfa
|
|
42 |
|
Cholecalciferol |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
67-97-0, 1406-16-2 |
5280795 10883523 |
Synonyms:
(+)-Vitamin D3
(1S,3Z)-3-[(2E)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(1R)-1,5-DIMETHYLHEXYL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-1-CYCLOHEXANOL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(1R)-1,5-DIMETHYLHEXYL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENECYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-{2-[(1R,4E,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-OCTAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE}-4-METHYLIDENECYCLOHEXAN-1-OL
(3 beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3BETA,Z,7E)-9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-OL
(3Β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5E,7E)-9,10-SECOCHOLESTA-5,7,10-TRIEN-3-OL
(5Z,7E)-(3S)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
3-BETA,Z,7E-9,10-SECOCHOLESTR-5,7,10(19)-TRIEN-3-OL
7-DEHYDROCHOLESTEROL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3BETA-OL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-BETA-OL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-OL
9,10-SECOCHOLESTA-5,7,10-TRIEN-3-OL
ACCRETE D3
ACIFEROL D3
ACTIVATED
Activated 7-dehydrocholesterol
ADCAL-D3
ARACHITOL
AVITICOL
BIOLIFE VITAMIN D3
BIO-VITAMIN D3
CACIT D3
CALCEOS
CALCICHEW D3
CALCICHEW D3 FTE
CALCICHEW D3 ONCE DAILY
CALCI-D
Calciferol
Calciol
CALDRINK D3
CALFOVIT D3
CC
Cholecalciferol
CHOLECALCIFEROL D3
Cholecalciferols
Cholecalciferolum
COLECAL D3
Colecalciferol
Colecalciferolum
COLEKAL-D3
COLEVIT D3
CUBICOLE D3
D3 LEMON MELTS
D3-50
D3-VIGANTOL
DEKRISTOL
DELSTEROL
Delta-D
DEPARAL
DESUNIN
DEVARON
Dihydrocholesterol
DLUX 400
D-MAX
D-TRACETTEN
|
D-VIT3
EBIVIT
E-D3
EVACAL D3
FERACOL
FULTIUM DAILY D3
FULTIUM-D3
GRANUVIT D3
HUX D3
INVITA D3
ISO D3
KORA LIQUID
MICRO-DEE
NATECAL D3
NATURE'S REMEDY VITAMIN D3
NEO-D
NPHD3
NSC-375571
Oleovitamin D3
OSTEOCAPS D3
PLENACHOL
PRO D3
PRO D3 FOLIC
PRO D3 FORTE
PROVITINA
QUINTOX
RICKETON
ROYALVIT D3
STEXEROL-D3
STIVIT-D3
SUNVIT-D3 1,000
SUNVIT-D3 10,000
SUNVIT-D3 2,000
SUNVIT-D3 20,000
SUNVIT-D3 3,000
SUNVIT-D3 400
SUNVIT-D3 5,000
SUNVIT-D3 50,000
SUNVIT-D3 800
SYNERVIT-D3
THEICAL D-3
THORENS
TRIVITAN
VIDDE-3-HYDROSOL
VI-DE3
VIDEKHOL
VIGANTOL
VIGANTOLETTEN
VIGANTOLETTEN 500
VIGORSAN
VIT D3 STREULI
VITA-D3
VITAMIN D
Vitamin D 3
VITAMIN D ASSAY SYSTEM SUITABILITY
Vitamin D NOS
Vitamin D, unspecified form
Vitamin D3
Vitamin D-3
VITINC DAN-DEE-3
ZYMAD
δ-D
|
|
43 |
|
Ergocalciferol |
Approved, Nutraceutical |
Phase 2 |
|
50-14-6 |
5280793 |
Synonyms:
(+)-Vitamin D2
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(E,2R,5R)-5,6-DIMETHYLHEPT-3-EN-2-YL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENECYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(E,2R,5R)-5,6-DIMETHYLHEPT-3-EN-2-YL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(E,1R,4R)-1,4,5-TRIMETHYLHEX-2-ENYL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-1-CYCLOHEXANOL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(E,1R,4R)-1,4,5-TRIMETHYLHEX-2-ENYL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-{2-[(1R,3AS,4E,7AR)-1-[(2R,3E,5R)-5,6-DIMETHYLHEPT-3-EN-2-YL]-7A-METHYL-OCTAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE}-4-METHYLIDENECYCLOHEXAN-1-OL
(3b,5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(3Β,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-Seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
22-Tetraen 3beta 9,10,secoergosta-5,7,10(19)-ol
4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3ah)-indanylidene]ethylidene]-cyclohexanol
9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol
Activated ergosterol
beta-Ol
Buco-D
Calciferol
CALCIFEROL IN ARACH OIL
Calciferols
Calciferon 2
CALTRATE
Condacaps
Condocaps
Condol
Crtron
Crystallina
D2, Vitamin
Daral
D-Arthin
Davitamon D
Davitin
Decaps
Dee-osterol
Dee-ron
Dee-ronal
Dee-roual
delta-Arthin
Deltalin
delta-Tracetten
De-rat concentrate
Deratol
Detalup
D-FORTE
Diactol
Divit urto
Doral
Drisdol
D-Tracetten
ECIFEROL D2
Ercalciol
|
Ergocalciferol
ERGOCALCIFÉROL
Ergocalciferol oil
Ergocalciferols
Ergocalciferolum
ERGO-D2
ERGORAL D2
Ergorone
Ergosterol activated
Ergosterol irradiated
Ertron
Fortodyl
Geltabs
Hi-deratol
Infron
Irradiated ergosta-5,7,22-trien-3beta-ol
LANES
Metadee
Mina D2
Mulsiferol
Mykostin
Novovitamin-D
NSC-62792
Oleovitamin D
OLEOVITAMIN D, SYNTHETIC
Oleovitamin D2
Osteil
Ostelin
OSTO-D2
Radiostol
Radstein
Radsterin
Rodine C
Shock-ferol
Shock-ferol sterogyl
Sterogyl
STEROGYL 15H
STEROGYL-15
Synthetic vitamin D
Uvesterol D
Uvesterol-D
Vio D
Vio-D
Viostdrol
Viosterol
Viosterol in oil
VITAMIN D
Vitamin D 2
Vitamin D2
Vitamina D2
Vitavel-D
|
|
44 |
|
Ornithine |
Approved, Nutraceutical |
Phase 1, Phase 2 |
|
3184-13-2, 70-26-8 |
6262 |
Synonyms:
(+)-S-ORNITHINE
(2S)-2,5-DIAMINOPENTANOIC ACID
(S)-2,5-DIAMINOPENTANOATE
(S)-2,5-DIAMINOPENTANOIC ACID
(S)-2,5-Diaminovalerate
(S)-2,5-DIAMINOVALERIC ACID
(S)-A,D-DIAMINOVALERATE
(S)-A,D-DIAMINOVALERIC ACID
(S)-a,delta-Diaminovalerate
(S)-a,delta-Diaminovaleric acid
(S)-a,Δ-diaminovalerate
(S)-a,Δ-diaminovaleric acid
(S)-alpha,delta-Diaminovalerate
(S)-ALPHA,DELTA-DIAMINOVALERIC ACID
(S)-ORNITHINE
(S)-Α,δ-diaminovalerate
(S)-Α,Δ-DIAMINOVALERIC ACID
2,5 Diaminopentanoic acid
2,5-Diaminopentanoic acid
5-AMINO-L-NORVALINE
|
L-(-)-ORNITHINE
levo-ornithine
L-Ornithine
ORNITHINE
Ornithine dihydrochloride, (L)-isomer
Ornithine hydrochloride, (D)-isomer
Ornithine hydrochloride, (DL)-isomer
Ornithine hydrochloride, (L)-isomer
Ornithine monoacetate, (L)-isomer
Ornithine monohydrobromide, (L)-isomer
Ornithine monohydrochloride, (D)-isomer
Ornithine monohydrochloride, (DL)-isomer
Ornithine phosphate (1:1), (L)-isomer
Ornithine sulfate (1:1), (L)-isomer
Ornithine, (D)-isomer
Ornithine, (DL)-isomer
Ornithine, (L)-isomer
Ornithinum
Ornitina
|
|
45 |
|
Lysine |
Approved, Nutraceutical |
Phase 1, Phase 2 |
|
56-87-1 |
5962 |
Synonyms:
(+)-S-Lysine
(S)-2,6-Diaminohexanoate
(S)-2,6-Diamino-hexanoate
(S)-2,6-Diaminohexanoic acid
(S)-2,6-Diamino-hexanoic acid
(S)-a,e-Diaminocaproate
(S)-a,e-Diaminocaproic acid
(S)-a,epsilon-Diaminocaproate
(S)-a,epsilon-Diaminocaproic acid
(S)-alpha,epsilon-Diaminocaproate
(S)-alpha,epsilon-Diaminocaproic acid
(S)-Lysine
(S)-Α,epsilon-diaminocaproate
(S)-Α,epsilon-diaminocaproic acid
(S)-α,ε-diaminocaproic acid
2,6-Diaminohexanoate
2,6-Diaminohexanoic acid
6-Amino-aminutrin
6-Amino-L-norleucine
6-Ammonio-L-norleucine
Acetate, lysine
alpha-Lysine
|
a-Lysine
Aminutrin
Enisyl
H-Lys-OH
K
L Lysine
L-(+)-Lysine
L-2,6-Diainohexanoate
L-2,6-Diainohexanoic acid
L-2,6-Diaminocaproate
L-2,6-Diaminocaproic acid
L-Lys
L-Lysin
L-Lysine
Lys
Lysina
Lysine
Lysine acetate
Lysine acid
Lysine hydrochloride
Lysinum
|
|
46 |
|
D-Tyrosine |
Approved, Experimental, Investigational, Nutraceutical |
Phase 2 |
|
133585-56-5, 60-18-4, 556-02-5 |
1153 6057 |
Synonyms:
(-)-a-Amino-p-hydroxyhydrocinnamate
(-)-a-Amino-p-hydroxyhydrocinnamic acid
(-)-alpha-Amino-p-hydroxyhydrocinnamate
(-)-alpha-Amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamate
(−)-α-amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamic acid
(2S)-2-Amino-3-(4-hydroxyphenyl)propanoate
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
(2S)-2-AMINO-3-(4-HYDROXYPHENYL)PROPIONIC ACID
(2S)-2-AZANYL-3-(4-HYDROXYPHENYL)PROPANOIC ACID
(R)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(R)-3-(p-Hydroxyphenyl)alanine
(S)-(-)-Tyrosine
(S)-2-Amino-3-(p-hydroxyphenyl)propionate
(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(S)-3-(p-Hydroxyphenyl)alanine
(S)-a-Amino-4-hydroxybenzenepropanoate
(S)-a-Amino-4-hydroxy-benzenepropanoate
(S)-a-Amino-4-hydroxybenzenepropanoic acid
(S)-a-Amino-4-hydroxy-benzenepropanoic acid
(S)-alpha-Amino-4-hydroxybenzenepropanoate
(S)-alpha-Amino-4-hydroxy-benzenepropanoate
(S)-alpha-amino-4-Hydroxybenzenepropanoic acid
(S)-alpha-Amino-4-hydroxy-benzenepropanoic acid
(S)-Tyrosine
(S)-Α-amino-4-hydroxybenzenepropanoate
(S)-α-amino-4-hydroxybenzenepropanoic acid
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid
2-Amino-3-(4-hydroxyphenyl)propanoate
|
2-Amino-3-(4-hydroxyphenyl)propanoic acid
2-Amino-3-(p-hydroxyphenyl)propionate
2-Amino-3-(p-hydroxyphenyl)propionic acid
3-(4-Hydroxyphenyl)-L-alanine
3-(p-Hydroxyphenyl)alanine
4-hydroxy-L-phenylalanine
6-Hydroxysandoricin
Benzenepropanoate
Benzenepropanoic acid
D-Tyr
D-Tyrosin
FEMA NO. 3736
L Tyrosine
LEVODOPA IMPURITY, L-TYROSINE-
LEVODOPA RELATED COMPOUND L-TYROSINE
L-p-Tyrosine
L-Tyrosin
L-tyrosine
Methyl 2-[5,11-bis(acetyloxy)-13-(furan-3-yl)-16-hydroxy-6,6,8,12-tetramethyl-17-methylidene-15-oxo-2,14-dioxatetracyclo[7.7.1.0¹,¹².0³,⁸]heptadecan-7-yl]-2-hydroxyacetic acid
NSC-82624
Para tyrosine
Para-tyrosine
p-Tyrosine
Tirosina
Tyr
Tyrosin
Tyrosine
Tyrosine, L isomer
Tyrosine, L-isomer
Tyrosinum
Y
|
|
47 |
|
Cadexomer iodine |
Experimental |
Phase 2 |
|
94820-09-4 |
|
Synonyms:
|
48 |
|
Spartalizumab |
Investigational |
Phase 2 |
|
1935694-88-4 |
|
Synonyms:
ANTI-PD1 MONOCLONAL ANTIBODY PDR001
NPV-PDR001|NPVPDR001|PDR-001|PDR001
NVP-LZV184
|
PDR001
PDR-001
SPARTALIZUMAB
|
|
49 |
|
Calcitonin gene-related peptide |
Investigational |
Phase 2 |
|
83652-28-2 |
91976570 |
Synonyms:
2-{[2-({6-amino-2-[(2-{[2-({2-[(2-{[2-({[1-(2-{[2-({2-[(2-{[6-amino-2-({2-[(2-{[2-({2-[(2-{[2-({2-[(2-{[2-({2-[(2-{[2-({2-[(2-{[2-({2-[({19-[(2-amino-1-hydroxypropylidene)amino]-16-(carboxymethyl)-6,9,12,15,18-pentahydroxy-7,13-bis(1-hydroxyethyl)-10-methyl-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaen-4-yl}(hydroxy)methylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-1,3-dihydroxybutylidene]amino}-1-hydroxy-3-(1H-imidazol-5-yl)propylidene)amino]-5-carbamimidamido-1-hydroxypentylidene}amino)-1-hydroxy-4-methylpentylidene]amino}-1-hydroxypropylidene)amino]-1-hydroxyethylidene}amino)-1-hydroxy-4-methylpentylidene]amino}-1-hydroxy-4-methylpentylidene)amino]-1,3-dihydroxypropylidene}amino)-5-carbamimidamido-1-hydroxypentylidene]amino}-1,3-dihydroxypropylidene)amino]-1-hydroxyethylidene}amino)-1-hydroxyethylidene]amino}-1-hydroxy-3-methylbutylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-1-hydroxyhexylidene]amino}-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene)amino]-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene}amino)-1-hydroxy-3-phenylpropylidene]amino}-3-methylbutanoyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)-1,3-dihydroxybutylidene]amino}-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-1-hydroxyethylidene]amino}-1,3-dihydroxypropylidene)amino]-1-hydroxyhexylidene}amino)-1-hydroxypropylidene]amino}-3-phenylpropanoate
Calcitonin gene related peptide
Calcitonin-gene-related peptide
|
|
|
50 |
|
Vitamins |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 136)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
IN-PACT CORO INtimal hyPerplasia evAluated by oCT in de Novo COROnary Lesions Treated by Drug-eluting Balloon and Bare-metal Stent |
Unknown status |
NCT01057563 |
Phase 4 |
|
2 |
A-PACT: The Use of Inhaled Aztreonam to Eliminate or Decrease the Bacterial Burden of Pseudomonas Aeruginosa in Children With a Tracheostomy Tube. |
Terminated |
NCT03158116 |
Phase 4 |
Inhaled Aztreonam |
3 |
Decision Aid on Radioactive Iodine Treatment for Early Stage Papillary Thyroid Cancer (Randomized Controlled Trial) |
Completed |
NCT01083550 |
Phase 2, Phase 3 |
|
4 |
CSP #563 - Prazosin and Combat Trauma PTSD (PACT) |
Completed |
NCT00532493 |
Phase 3 |
prazosin |
5 |
Non-small Cell Lung Cancer Study US75 (Z-PACT) |
Completed |
NCT00086268 |
Phase 3 |
zoledronic acid;Taxotere;Carboplatin |
6 |
Pediatric Asthma Controller Trial (PACT) |
Completed |
NCT00272506 |
Phase 3 |
inhaled corticosteroid;long-acting beta2-agonist |
7 |
Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements |
Completed |
NCT00559949 |
Phase 2 |
Selumetinib |
8 |
Phase 2 Study of Routine Oral Calcium and Vitamine D Supplements to Prevent Hypocalcemia After Total Thyroidectomy in Papillary Thyroid Carcinoma Patients |
Completed |
NCT00630214 |
Phase 2 |
|
9 |
A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma |
Completed |
NCT00104871 |
Phase 2 |
Bortezomib |
10 |
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma |
Completed |
NCT01502410 |
Phase 2 |
sorafenib tosylate |
11 |
Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma |
Completed |
NCT00887107 |
Phase 2 |
Sorafenib (nexavar) |
12 |
Thyroid Gland Removal With or Without Central Lymph Node Dissection in Treating Patients With Node Negative Thyroid Cancer |
Completed |
NCT02138214 |
Phase 2 |
|
13 |
Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation |
Completed |
NCT00519896 |
Phase 2 |
sunitinib malate |
14 |
Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine |
Completed |
NCT00085293 |
Phase 2 |
Decitabine |
15 |
Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma |
Completed |
NCT00134043 |
Phase 2 |
vorinostat |
16 |
An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor Vemurafenib in Patients With Metastatic or Unresectable Papillary Thyroid Cancer (PTC) Positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine |
Completed |
NCT01286753 |
Phase 2 |
Vemurafenib |
17 |
Sutent Adjunctive Treatment of Differentiated Thyroid Cancer |
Completed |
NCT00668811 |
Phase 2 |
SU011248, Sutent |
18 |
A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma |
Completed |
NCT00098813 |
Phase 2 |
romidepsin |
19 |
A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma |
Completed |
NCT00118248 |
Phase 2 |
tanespimycin |
20 |
The Participant Agreement for Contact Tracing (PACT) Study: Enhancing Partner Notification Services. |
Completed |
NCT00207493 |
Phase 1, Phase 2 |
|
21 |
A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors |
Recruiting |
NCT03899792 |
Phase 1, Phase 2 |
LOXO-292 |
22 |
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors |
Recruiting |
NCT04731467 |
Phase 1, Phase 2 |
CM-24 and Nivolumab - Dose Escalation;CM-24 and Nivolumab - Expansion;CM-24, Nivolumab, and Nab paclitaxel - Expansion;CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion |
23 |
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer |
Recruiting |
NCT05500508 |
Phase 1, Phase 2 |
AMXT1501;DFMO |
24 |
Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid Cancer |
Recruiting |
NCT04544111 |
Phase 2 |
Trametinib;Dabrafenib;PDR001 |
25 |
Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy |
Recruiting |
NCT02593175 |
Phase 2 |
Carboplatin;Paclitaxel |
26 |
A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial |
Recruiting |
NCT03753919 |
Phase 2 |
Durvalumab;Tremelimumab |
27 |
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements |
Active, not recruiting |
NCT02568267 |
Phase 2 |
Entrectinib |
28 |
A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors |
Active, not recruiting |
NCT03037385 |
Phase 1, Phase 2 |
pralsetinib (BLU-667) |
29 |
A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma |
Active, not recruiting |
NCT01723202 |
Phase 2 |
dabrafenib;trametinib |
30 |
A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen for Newly Diagnosed Primary Triple-Negative Inflammatory Breast Cancer |
Active, not recruiting |
NCT02876107 |
Phase 2 |
Carboplatin;Paclitaxel |
31 |
Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma |
Terminated |
NCT00095693 |
Phase 2 |
sorafenib tosylate |
32 |
Randomized Controlled Trial of Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in Patients With Low-risk Papillary Thyroid Cancer |
Terminated |
NCT02408887 |
Phase 2 |
|
33 |
Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer |
Terminated |
NCT03630120 |
Phase 2 |
Lenvatinib;Sorafenib;Cabozantinib;Vandetanib |
34 |
Radiofrequency Ablation for Low Risk Papillary Thyroid Cancer: A Pilot Study |
Unknown status |
NCT00103155 |
Phase 1 |
|
35 |
A Phase I Dose Escalation Trial to Determine if Imatinib Treatment Restores Sodium Iodide Symporter Function and Sensitivity to Radioiodine Treatment in Metastatic Thyroid Cancer Patients |
Unknown status |
NCT03469011 |
Phase 1 |
Imatinib Oral Tablet |
36 |
A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake |
Completed |
NCT01413113 |
Phase 1 |
pazopanib hydrochloride |
37 |
A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer |
Completed |
NCT00470496 |
Phase 1 |
HPPH;photodynamic therapy |
38 |
A Phase I Trial of Herceptin and Interleukin-12 |
Completed |
NCT00004074 |
Phase 1 |
|
39 |
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL281 Administered Orally to Subjects With Solid Tumors |
Completed |
NCT00451880 |
Phase 1 |
XL281;famotidine |
40 |
A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors |
Completed |
NCT01100619 |
Phase 1 |
rosiglitazone;XL184 |
41 |
Detection of Thyroid Cancer and Central Lymph Node Metastases Using EMI-137 Enhanced Molecular Fluorescent Guided Imaging: a Multicentre Feasibility and |
Completed |
NCT03470259 |
Phase 1 |
IV adminstration of EMI-137 |
42 |
Phase 1 Study of X-PACT (X-ray Psoralen Activated Cancer Therapy) for Intra-tumoral Injection of Superficial Tumors in Patients With Advanced Head and Neck Cancer, Breast Cancer, Soft Tissue Sarcoma or Melanoma |
Recruiting |
NCT04389281 |
Phase 1 |
|
43 |
A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT) |
Active, not recruiting |
NCT02791334 |
Phase 1 |
LY3300054;Ramucirumab;Abemaciclib;Merestinib;LY3321367 |
44 |
Evaluation of Accuracy of One-Step Nucleic Acid Amplification (OSNA) in Diagnosis of Lymph Node Metastases of Papillary Thyroid Carcinoma |
Unknown status |
NCT03889769 |
|
|
45 |
Is Routine Dissection of Central Lymph Node Necessary for Papillary Thyroid Carcinoma, T1-2 N0? |
Unknown status |
NCT04336696 |
|
|
46 |
The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma |
Unknown status |
NCT04076514 |
|
|
47 |
Differences Protein Expression in Papillary Thyroid Carcinoma |
Unknown status |
NCT02814032 |
|
|
48 |
99mTechnetium-MIBI SPECT-CT for Pre-operative Evaluation of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma; A Pilot Study |
Unknown status |
NCT00984191 |
|
|
49 |
Clinical Investigations on Cytokin-Gradients in Hypo/Euthyroid Patients. Evaluation of Expression of Different Pro-and Anti-Inflammatory Cyto-/Chemokines in Skin Wounds After Surgery of Benign Goitres (Struma Multinodosa) or Malignant Diseases of Thyroid Gland (Papillary Thyroid Carcinoma) in Correlation to the Status of Wound Healing of the Neck Wound |
Unknown status |
NCT00929318 |
|
|
50 |
Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma |
Unknown status |
NCT01417442 |
Early Phase 1 |
|
|